Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail

Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail

July 10, 2026Posted inBiotechnology

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study.

Post navigation

Previous Post
curtin-and-octave-team-up-to-train-future-digital-innovators Curtin and Octave team up to train future digital innovators
Next Post
Study Explores Traditional Chinese Medicine for Treating Post-COVID Syndrome study-explores-traditional-chinese-medicine-for-treating-post-covid-syndrome

Recent Posts

  • Pycnogenol Reduces Neurobehavioral and Liver Damage from Thioacetamide Exposure
  • Norwegian Stakeholders Review Guidelines to Prevent Elder Abuse
  • Physiatrists Evolve from Team Players to Leaders in Parkinson’s Care
  • Trends and Advances in Pediatric Mycoplasma pneumoniae Pneumonia Research
  • Long-Term Home Deep Sleep Modulation Shows Promise in Parkinson’s Disease

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top